Strategically, Vivos achieved notable milestones including receiving FDA clearance for its devices to treat moderate to severe obstructive sleep apnea in children, and the introduction of new medical ...
Vivos' cost-cutting initiatives also led to a $1 million or 27% year-over-year reduction in operating loss, versus the third quarter of 2023. For the nine months ended September 30, 2024 operating ...
(“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for ...
The analysts see ways that Livanova could differentiate its device but said the company “may have a difficult time breaking into the sleep apnea market.” Livanova stopped enrollment in the trial ahead ...